By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. Petrelintide is an investigational compound. Its safety and efficacy have not been approved for marketing by the FDA or other regulators for any indication. Clinical trial results are summarized here as published research data, not as medical advice.
Quick answer
Petrelintide (development code ZP8396; Roche registry code RO7895515 in later trials) is an investigational, long-acting human amylin analogue designed for once-weekly subcutaneous administration in clinical studies. It is being co-developed by Zealand Pharma and Roche. Phase 2 ZUPREME-1 results in people with overweight or obesity without type 2 diabetes were published in The Lancet Diabetes & Endocrinology (online ~29 September 2026); a registrational Phase 3 ZUPREME program has been initiated. Petrelintide is not the same molecule as cagrilintide (Novo Nordisk) or eloralintide (Eli Lilly), even though all three engage amylin-pathway biology.
Identity, synonyms, and chemical descriptors
WHO INN and development codes
| Label | Value |
|---|---|
| Proposed INN | Petrelintide (WHO Proposed INN List 129; descriptor: amylin analogue) [WHO PL129/pl129.pdf)] |
| Primary development code | ZP8396 / ZP-8396 (Zealand) [Zealand pipeline] |
| Roche / later registry synonym | RO7895515 (appears with ZP8396 on Roche-sponsored records; confirm on the specific ClinicalTrials.gov record when citing) |
| Other depositor synonyms | GTPL13804, EX-A12430 [PubChem] |
Practical search tip for labs: literature and registries may index the same entity under petrelintide, ZP8396, or RO7895515. Treat these as linked names for one development candidate — not as three different peptides — and always reconcile against structure / mass data on the COA for any research lot.
Molecular descriptors (public chemical records)
Public compound records list petrelintide with molecular formula C185H305N49O61, an approximate molecular weight near 4192 g/mol, and PubChem CID 172915807 [PubChem]. The computed structural description includes a long-chain acyl (fatty-acid) moiety consistent with an acylated peptide designed for albumin binding and extended exposure.
CAS caveat: as of the public PubChem snapshot used for this draft, a universally cited CAS number was not prominently listed among depositor synonyms. Do not invent a CAS for catalog copy. Prefer INN + development code + exact mass / sequence documentation on the batch COA.
These formula and mass figures describe the intact modified peptide as deposited in the chemical database. Counterions, residual water, and salt form change the weighed vial mass relative to peptide content — HPLC area-% purity alone is not peptide content by weight.
How it differs from native human amylin
Native human amylin (islet amyloid polypeptide, IAPP) is a 37-residue hormone co-secreted with insulin after nutrient intake. It is a difficult pharmaceutical starting point: it is prone to aggregation / fibrillation and has a short circulating lifetime. Petrelintide was engineered as a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH, with design work focused on chemical stability while retaining in-vitro and in-vivo potency [J. Med. Chem. abstract].
Sponsor materials emphasize chemical and physical stability with no fibrillation around neutral pH, which is intended to support co-formulation and co-administration with other peptides [Zealand pipeline; Roche 5 Mar 2026].
Mechanism: amylin receptor biology
Amylin, CTR, and RAMP complexes (AMY1 / AMY2 / AMY3)
Amylin receptors are not standalone single-subunit proteins. They form when the calcitonin receptor (CTR) associates with a receptor activity-modifying protein (RAMP):
| Complex | Composition (simplified) |
|---|---|
| CTR | Calcitonin receptor without a RAMP |
| AMY1R | CTR + RAMP1 |
| AMY2R | CTR + RAMP2 |
| AMY3R | CTR + RAMP3 |
This architecture is reviewed in IUPHAR-facing pharmacology of the calcitonin / CGRP peptide family [Hay et al., Br J Pharmacol 2018]. Subtype preference, species differences, and assay conditions can all change apparent potency rankings — so “selective” or “balanced” claims must always name the receptors and systems that were actually tested.
Reported pharmacology for petrelintide
Peer-reviewed Phase 1 framing describes petrelintide as a ~37-amino-acid (~4.2 kDa), long-acting, acylated analogue of human amylin with agonistic effects at amylin receptors (AMY1 and AMY3) and the calcitonin receptor relative to human amylin and human calcitonin in the reported systems, and with albumin binding via a fatty-acid moiety that prolongs exposure [Brændholt Olsen et al., Diabetes Obes Metab].
Hedges that belong in any careful research summary:
- In-vitro EC50 / binding values are assay-specific (cell background, expression level, albumin, readout).
- Rodent food-intake or body-composition findings do not translate into a human or veterinary use plan.
- Petrelintide’s public differentiation story centers on stability and neutral-pH formulability more than on a Lilly-style “AMY1R-preferring” headline. Do not copy eloralintide selectivity language onto petrelintide without petrelintide-specific assay tables.
Why developers discuss satiety pathways separately from incretin appetite pathways
Sponsor and review literature frame amylin-receptor activation as contributing to satiety / meal termination, delayed gastric emptying, and glucagon-related effects, and as mechanistically distinct from GLP-1 receptor agonist appetite pathways [Zealand pipeline; sponsor-cited physiology such as Mathiesen et al. and Roth et al. PNAS 2008]. That framing explains why combination programs exist. It is not a license to market petrelintide as “better than GLP-1” or as a consumer weight-loss product.
Neutral-pH stability and co-formulation rationale
Design publications and sponsor releases repeatedly state that petrelintide was optimized for chemical/physical stability at approximately neutral pH without fibrillation, enabling co-formulation exploration with other peptide therapeutics [J. Med. Chem.; Zealand]. Roche and Zealand have described combination development with Roche’s GLP-1/GIP dual agonist enicepatide (CT-388), with a Phase 2 combination trial stated for initiation in the second half of 2026 [Roche; Zealand GlobeNewswire 29 Sep 2026].
Development landscape: Zealand, Roche, and the ZUPREME program
Partnership facts (2025 collaboration)
In 2025, Zealand Pharma and Roche entered an exclusive collaboration and licensing agreement to co-develop and co-commercialize petrelintide for people living with overweight and obesity, including combination products [Roche 5 Mar 2026; Zealand pipeline]. Zealand’s pipeline page states the collaboration covers co-development and co-commercialization in the U.S. and Europe [Zealand].
Clinical program map
| Program | Population (stated) | Phase | Status note (as of sources below) |
|---|---|---|---|
| ZUPREME-1 | Overweight/obesity without type 2 diabetes | 2 | Peer-reviewed in Lancet Diabetes & Endocrinology ~29 Sep 2026; NCT06662539 completed |
| ZUPREME-2 | Overweight/obesity with type 2 diabetes | 2 | Company topline ~7 Oct 2026; full peer-reviewed paper pending [GlobeNewswire] |
| ZUPREME-3 | Overweight/obesity without T2D (~3,900 planned) | 3a | Registrational program initiated with Roche [BioSpace / Zealand PR] |
| ZUPREME-4 | Overweight/obesity with T2D (~600 planned) | 3a | Same initiation release |
| ZUPREME-5 | Overweight/obesity with established CVD (~2,500 planned; longer event phase) | 3a | Same initiation release; primary efficacy assessment at week 64 |
| Combo + enicepatide (CT-388) | Overweight/obesity | 2 planned | Initiation stated for H2 2026 [Roche] |
Phase 3a monotherapy primary endpoint (stated): percentage change in body weight from baseline to week 64; three trials expected to enroll about 7,000 participants in total [BioSpace / Zealand PR].
ObesityWeek 2026 (14–17 November) is a near-term scientific meeting window where amylin-pathway and combination abstracts may appear; treat conference posters as preliminary until peer-reviewed [ObesityWeek].
ZUPREME-1 evidence map (published research data — not advice)
Every figure below is a trial-reported outcome under the stated analysis. None of it is a dosing schedule, eligibility recommendation, or product claim for research vials.
Design at a glance
From ClinicalTrials.gov and the Lancet abstract:
- Randomized, double-blind, placebo-controlled, parallel-group, multinational, multicenter, dose-finding Phase 2 trial [CT.gov NCT06662539; Lancet article page00213-5/fulltext)].
- Sites in Poland, Romania, and the USA (abstract: 32 sites; Roche topline text also mentions enrollment across U.S./Poland/Romania) [Lancet abstract00213-5/fulltext); Roche].
- Adults ≥18 years with BMI ≥30 kg/m², or BMI ≥27 kg/m² with hypertension and/or dyslipidaemia; without type 2 diabetes (exclusion includes HbA1c ≥6.5% / diabetes history on CT.gov) [CT.gov].
- Randomization 5:1 to petrelintide maintenance doses 1.0–9.0 mg once weekly or placebo for 42 weeks including dose escalation [Lancet abstract00213-5/fulltext)].
- Primary endpoint: percentage change in body weight from baseline after 28 weeks [CT.gov; Lancet abstract00213-5/fulltext)].
- Screened 714; 493 randomly assigned; 485 received ≥1 dose [Lancet abstract00213-5/fulltext)].
- Dose-arm n (received ≥1 dose): 1.0 mg 79; 2.5 mg 81; 5.0 mg 83; 7.0 mg 79; 9.0 mg 82; placebo 81 [Lancet abstract00213-5/fulltext)].
- Baseline (abstract): 53% female; mean age 47 (SD 12); mean body weight 107.1 kg; mean BMI 36.7 kg/m² [Lancet abstract00213-5/fulltext)].
Trial completed 7 March 2026 per the abstract narrative; CT.gov lists completion 2026-03-07 [Lancet abstract00213-5/fulltext); CT.gov].
Efficacy numbers (Lancet abstract + labelled sponsor supplements)
Week 28 — primary (efficacy estimand), mean % body-weight change [Lancet abstract00213-5/fulltext)]:
| Arm | Mean % change (95% CI) | Estimated treatment difference vs placebo |
|---|---|---|
| Petrelintide 1.0 mg | −7.9% (−9.0 to −6.7) | −6.2% (−7.9 to −4.5) |
| Petrelintide 2.5 mg | −7.9% (−9.0 to −6.7) | −6.2% (−7.8 to −4.5) |
| Petrelintide 5.0 mg | −9.8% (−10.9 to −8.6) | −8.1% (−9.7 to −6.5) |
| Petrelintide 7.0 mg | −9.3% (−10.5 to −8.2) | −7.7% (−9.3 to −6.0) |
| Petrelintide 9.0 mg | −9.4% (−10.5 to −8.3) | −7.7% (−9.4 to −6.1) |
| Placebo | −1.7% (−2.8 to −0.5) | — |
Week 42: the abstract states body weight continued to decline, with reductions of up to −10.7% with petrelintide [Lancet abstract00213-5/fulltext)]. That “up to” language is an upper-bound summary, not a single dose-tagged point estimate in the open abstract text used for this draft. Zealand’s publication press release similarly reports mean reductions to week 42 of up to 10.7% vs 1.7% placebo (efficacy estimand) and up to 10.2% vs 1.4% under a treatment-policy estimand [Zealand GlobeNewswire 29 Sep 2026]. Roche’s earlier topline used the same 10.7% / 1.7% framing [Roche].
Sponsor-reported cardiometabolic secondaries (not substituted for Lancet tables): waist circumference reductions up to 10.8 cm vs 4.3 cm placebo; hsCRP reductions up to 41% vs 6%; triglycerides up to 21% vs 9%; pulse rate reduction up to 2.9 bpm vs +0.3 bpm placebo [Zealand GlobeNewswire 29 Sep 2026]. Treat these as sponsor press figures until verified against full-text tables (Lancet full text was not accessed for this draft).
Roche notes MRI body-composition change at week 42 as an exploratory endpoint and that female participants lost considerably more weight than male participants in this trial [Roche] — exploratory / subgroup observations, not a generalizable use claim.
Adverse-event signals as published (abstract)
From the Lancet abstract [Lancet abstract00213-5/fulltext)]:
| Event | Petrelintide (n = 404 pooled active) | Placebo |
|---|---|---|
| Nausea (most common) | 79 (20%) | 5 (6%) |
| Vomiting | 12 (3%) | 5 (6%) |
| Diarrhoea | 30 (7%) | 6 (7%) |
| Constipation | 28 (7%) | 3 (4%) |
| Deaths | None reported | — |
Interpretation discipline:
- “GI tolerability comparable to placebo apart from predominantly mild nausea during dose escalation” is the abstract’s interpretation, not a promise of zero GI events [Lancet abstract00213-5/fulltext)].
- Sponsor statements about “no vomiting / no GI discontinuations at the maximally effective dose” are dose-cohort-specific press claims [Roche; Zealand GlobeNewswire] — do not rewrite them as “petrelintide never causes vomiting.”
What the open abstract does not settle
- Full dose-by-dose week-42 efficacy table (needs full text).
- Graded AE severity tables and discontinuation reasons by arm (needs full text).
- Complete MRI / body-composition results (exploratory; Roche) [Roche].
- Long-term cardiovascular outcomes (Phase 3 ZUPREME-5 is designed for that question) [BioSpace / Zealand PR].
- Any valid cross-trial ranking versus eloralintide monotherapy or CagriSema combination results.
ZUPREME-2 and Phase 3
ZUPREME-2 topline (type 2 diabetes) — press only until peer review
Zealand’s 7 October 2026 release reports that once-weekly petrelintide met its primary endpoint in people with overweight or obesity and type 2 diabetes, with mean weight loss at week 28 of up to 9.2% (range across arms 7.4–9.2%) versus 2.0% placebo (efficacy estimand), and HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo (placebo-adjusted HbA1c reduction 0.61–0.88%). GI adverse-event discontinuation was reported as 1.9% vs 1.7% placebo [GlobeNewswire 7 Oct 2026].
Label clearly in any republication: company topline; full methods, dose tags, and AE tables await peer-reviewed publication.
Phase 3a ZUPREME-3 / 4 / 5 design intent
Per Zealand’s initiation release (with Roche): three registrational monotherapy trials; primary % body-weight change at week 64; optional OLE after ZUPREME-3/4 week-64 visits; ZUPREME-5 includes an event-maintenance phase that can extend up to ~3 years [BioSpace / Zealand PR]. Initiation ≠ approval.
Petrelintide vs cagrilintide vs eloralintide
All three are investigational, long-acting amylin-pathway peptides. They are not interchangeable reference standards.
| Dimension | Petrelintide | Cagrilintide | Eloralintide |
|---|---|---|---|
| Common code | ZP8396 | AM833 (historical) | LY3841136 |
| Originator / partners | Zealand Pharma + Roche | Novo Nordisk | Eli Lilly |
| Public design emphasis | Long-acting human amylin analogue; neutral-pH stability / anti-fibrillation; combo-ready formulation story [Zealand; J. Med. Chem.] | Long-acting amylin analogue with broader amylin/CTR pharmacology in comparative literature; major CagriSema combo dataset [Lancet 2021 abstract01751-7/abstract); NEJM CagriSema] | AMY1R-preferring vs AMY3R/CTR in reported human recombinant cAMP assays [SaiyanMed Elo hub] |
| Dosing concept in trials | Once weekly | Once weekly | Once weekly |
| Monotherapy evidence snapshot | Phase 2 ZUPREME-1 peer-reviewed [Lancet00213-5/fulltext)] | Phase 2 monotherapy + extensive combo Phase 3 | Phase 2 + Phase 3 ENLIGHTEN programs (see Elo hub) |
| Flagship combo theme | Enicepatide / CT-388 [Roche] | Semaglutide (CagriSema) [NEJM] | Incretin combinations (program-specific) |
Why cross-trial % weight loss is not a ranking
Trials differ in population (T2D yes/no), baseline BMI/sex mix, duration, escalation schedule, estimands (efficacy vs treatment-policy), rescue rules, and whether the amylin analogue is studied alone or fixed with an incretin. A “10.7% at 42 weeks” headline from ZUPREME-1 cannot be ranked against CagriSema or eloralintide Phase 2/3 figures as if they were head-to-head arms.
Related SaiyanMed research reading
- What Is Eloralintide
- Eloralintide vs Cagrilintide
- Eloralintide vs Retatrutide (different mechanism class — use only as contrast, not as amylin ranking)
- RUO listings (when purchasing reference tools for assays): Eloralintide product, Cagrilintide product
- Planned follow-up on this site: `/petrelintide-vs-cagrilintide/` (not published yet)
Analytical verification for research material
Why a vial label is not identity
“Petrelintide,” “ZP8396,” and marketing purity badges do not prove that a lyophilized powder matches the clinical development candidate. Acylated amylin analogues can fail by wrong sequence, incomplete acylation, isomer/epimer content, aggregation, or simple mislabeling. Appearance of the cake is not an analytical method.
Minimum COA packet (research buyer checklist)
| Item | Why it matters |
|---|---|
| Lot-matched COA | Must match the vial lot — not a “representative” PDF |
| RP-HPLC / UPLC purity + chromatogram | Area-% under a stated method; inspect shoulders |
| Intact-mass LC-MS | Observed vs theoretical mass for the intact acylated species |
| Peptide content / counterion / water | Separates peptide mass from salt and residual solvent |
| Third-party testing when available | Reduces conflict of interest vs in-house-only sheets |
| Traceability | Manufacture/test dates, method IDs, lab identity |
For complex modified peptides, a single HPLC purity number without mass identity is incomplete. Orthogonal methods (mapping, orthogonal chromatography, aggregate checks) become more important as structural complexity rises — the same quality philosophy used on SaiyanMed’s eloralintide research overview [Elo hub].
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture ingress, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, or study schedules.
Researcher decision tree (laboratory context)
Choosing an amylin-pathway reference tool
- Need a literature trail centered on human AMY1R preference in recombinant assays → start with eloralintide documentation (hub, vs cagrilintide).
- Need the broadest clinical + combination amylin dataset and CagriSema context → cagrilintide literature (product listing for RUO supply context).
- Need a Zealand/Roche amylin analogue case study emphasizing neutral-pH stability / co-formulation design plus ZUPREME Phase 2 peer-reviewed monotherapy data → petrelintide (this page).
Common lab failure modes
- Assuming name similarity means chemical identity (petrelintide ≠ cagrilintide ≠ eloralintide).
- Treating HPLC area-% as peptide content by weight.
- Comparing open-label or combination % weight-change headlines to monotherapy RCT primary endpoints.
- Using RUO documentation as a personal administration guide (prohibited).
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “Petrelintide is just another name for cagrilintide.” | Different sponsors, codes (ZP8396 vs AM833), and programs [Zealand; Lancet cagrilintide Phase 201751-7/abstract)]. |
| “10.7% means every dose and every participant.” | Abstract uses “up to −10.7%” at week 42; week-28 means are dose-specific (−7.9% to −9.8%) [Lancet abstract00213-5/fulltext)]. |
| “Placebo-like GI means no nausea.” | Nausea 20% vs 6% placebo in the abstract [Lancet abstract00213-5/fulltext)]. |
| “Phase 3 started, so it is approved / available as a medicine.” | Still investigational; Phase 3 initiation ≠ marketing authorization [Zealand PR]. |
| “A 99% online COA proves clinical-trial equivalence.” | Need lot-matched identity + purity + content appropriate to the intact acylated peptide. |
| “RUO vials are for personal weight loss.” | Explicitly out of scope for this page and for RUO supply. |
Glossary
- Amylin (IAPP): 37-residue peptide co-secreted with insulin from pancreatic β-cells.
- CTR / RAMP / AMY receptors: Calcitonin receptor ± RAMP1/2/3 forming AMY1/2/3 complexes.
- Acylation: Fatty-acid / linker attachment that can promote albumin binding and prolong exposure.
- Fibrillation: Aggregation into amyloid-like fibrils — a native amylin developability problem.
- Estimand: Precise definition of the treatment effect being estimated (e.g., efficacy vs treatment-policy).
- INN: WHO International Nonproprietary Name.
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
- RP-HPLC / LC-MS: Core purity and intact-mass identity methods for peptides.
FAQ
What is petrelintide?
Petrelintide is an investigational long-acting human amylin analogue (ZP8396) in clinical development by Zealand Pharma with Roche for chronic weight management research programs. It is not an approved medicine [Zealand; Lancet00213-5/fulltext)].
Is petrelintide the same as ZP8396?
Yes — ZP8396 is the primary Zealand development code for petrelintide [Zealand pipeline]. Roche-era records may also list RO7895515.
Is petrelintide FDA-approved?
No. Sponsor materials state it is investigational and not approved for marketing by regulatory authorities [Zealand].
How does petrelintide work in research descriptions?
It is described as an amylin-receptor-pathway agonist (AMY1/AMY3 and CTR activity reported relative to human ligands in published Phase 1 framing), with albumin binding via acylation supporting once-weekly clinical regimens [Brændholt Olsen et al.]. This is pharmacology context, not a use instruction.
What were the ZUPREME-1 results?
In the Phase 2 trial without type 2 diabetes, week-28 mean body-weight reductions were about −7.9% to −9.8% across petrelintide doses versus −1.7% placebo (efficacy estimand), with week-42 reductions of up to −10.7%; nausea was the most common adverse event (20% vs 6% placebo) [Lancet abstract00213-5/fulltext)].
What is the difference between petrelintide and cagrilintide?
Different companies, codes, and evidence bases: petrelintide is Zealand/Roche’s ZP8396 with a public stability/neutral-pH design story and ZUPREME program; cagrilintide is Novo Nordisk’s long-acting amylin analogue best known clinically via CagriSema combination data [NEJM]. See also Eloralintide vs Cagrilintide.
How does petrelintide compare with eloralintide?
Eloralintide (LY3841136) is publicly positioned around preferential human AMY1R activation in recombinant assays [Elo hub]. Petrelintide’s public emphasis is long-acting human amylin analogue stability and formulability. They are not the same peptide.
Who develops petrelintide?
Zealand Pharma originated the program; Roche is the 2025 collaboration partner for co-development and co-commercialization [Roche].
What Phase 3 trials are running?
The Phase 3a ZUPREME-3, ZUPREME-4, and ZUPREME-5 monotherapy trials were initiated to enroll roughly 7,000 participants across non-T2D, T2D, and CVD populations, with primary weight endpoints at week 64 [Zealand PR via BioSpace].
How should labs verify identity and purity?
Require a lot-matched COA with chromatogram-backed HPLC/UPLC purity and intact-mass LC-MS matching the theoretical acylated mass; prefer peptide content and orthogonal checks for complex analogues. Labels alone are insufficient.
Is petrelintide available for research use only?
Any research material offered by peptide suppliers — if offered — should be treated as RUO, not as clinical-trial drug product and not for human use. Regulatory status of the Zealand/Roche medicine candidate is separate from third-party research chemicals.
Does SaiyanMed sell petrelintide?
Not as a listed catalog SKU at the time of this draft. SaiyanMed publishes this page as research education within the amylin analogue cluster. For research-supply questions or to request notification if a verified RUO lot is listed later, contact support — do not assume stock from this article. Related RUO tools already on catalog: eloralintide, cagrilintide.
Key takeaways
- Petrelintide (ZP8396) is an investigational long-acting human amylin analogue from Zealand Pharma with Roche — not approved, not interchangeable with cagrilintide or eloralintide.
- ZUPREME-1 provides peer-reviewed Phase 2 monotherapy evidence (week-28 dose-ranging efficacy; week-42 “up to −10.7%”; nausea 20% vs 6% placebo) [Lancet abstract00213-5/fulltext)].
- Phase 3 ZUPREME-3/4/5 is underway; ZUPREME-2 T2D data remain topline until peer review.
- Lab buyers should demand lot-matched HPLC + MS identity documentation — never treat a name on a vial as proof.
- This page is RUO education. It is not a protocol and not a product claim that SaiyanMed currently stocks petrelintide.
Related reading & research inquiry
- What Is Eloralintide
- Eloralintide vs Cagrilintide
- Eloralintide vs Retatrutide
- Eloralintide RUO product · Cagrilintide RUO product
CTA (SKU-gated): If your laboratory needs a verified amylin-analogue reference material or wants to be notified if RUO petrelintide is listed after supplier COA review (≥99% HPLC with MS identity), contact SaiyanMed research support. We will not invent inventory on this page.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and analytical-quality information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. Petrelintide remains investigational as a therapeutic candidate.
References
- WHO Proposed INN List 129 — https://www.who.int/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf
- PubChem Petrelintide — https://pubchem.ncbi.nlm.nih.gov/compound/Petrelintide
- Zealand Pharma petrelintide pipeline — https://www.zealandpharma.com/pipeline/petrelintide/
- Eriksson et al. / J. Med. Chem. petrelintide development — https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5c01185
- Brændholt Olsen et al., Diabetes Obes Metab — https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70753
- Hay et al., IUPHAR Review 25 — https://pmc.ncbi.nlm.nih.gov/articles/PMC5740251/
- Roche ZUPREME-1 topline (5 Mar 2026) — https://www.roche.com/media/releases/med-cor-2026-03-05
- Zealand GlobeNewswire Lancet publication / EASD (29 Sep 2026) — https://www.globenewswire.com/news-release/2026/09/29/3371443/0/en/zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-endocrinology.html
- Lancet Diabetes & Endocrinology ZUPREME-1 article — https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00213-5/fulltext (full text not accessed for this draft; abstract used)
- ClinicalTrials.gov NCT06662539 — https://clinicaltrials.gov/study/NCT06662539
- Zealand ZUPREME-2 topline (7 Oct 2026) — https://www.globenewswire.com/news-release/2026/10/07/3376750/0/en/zealand-pharma-announces-positive-phase-2-zupreme-2-topline-results-for-amylin-analog-petrelintide-in-people-with-overweight-or-obesity-and-type-2-diabetes.html
- Zealand Phase 3 initiation (BioSpace syndicate) — https://www.biospace.com/press-releases/zealand-pharma-announces-initiation-of-the-registrational-phase-3-zupreme-program-of-petrelintide-in-people-with-overweight-or-obesity
- Cagrilintide Phase 2 Lancet abstract — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01751-7/abstract
- CagriSema NEJM — https://www.nejm.org/doi/full/10.1056/NEJMoa2502081
- Mathiesen et al. (sponsor-cited physiology) — https://doi.org/10.1530/EJE-21-1070
- Roth et al. PNAS 2008 (sponsor-cited) — https://www.pnas.org/doi/10.1073/pnas.0706473105
- ObesityWeek — https://obesityweek.org/
- SaiyanMed internal — https://saiyanmed.com/what-is-eloralintide/ · https://saiyanmed.com/eloralintide-vs-cagrilintide/ · https://saiyanmed.com/eloralintide-vs-retatrutide/ · https://saiyanmed.com/product/eloralintide/ · https://saiyanmed.com/product/cagrilintide/